Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

Blood (2019) 134 (Supplement_1): 48.

https://doi.org/10.1182/blood-2019-125967

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, Anne Lehman, Grace Jeschke, PhD, John D. Crispino, PhD MBA, Thierry Besson, PhD, Sarah K. Tasian, MD, Martin Carroll, MD

Blood (2019) 134 (Supplement_1): 2742.

https://doi.org/10.1182/blood-2019-123475

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response

Dennis J. Eastburn, PhD, Christine M. McMahon, MD, Robert Durruthy-Durruthy, PhD, Martin Carroll, MD, Catherine C. Smith, MD, Alexander E. Perl, MD

Blood (2018) 132 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2018-99-119869

Published: 2018

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 717.

https://doi.org/10.1182/blood.V130.Suppl_1.717.717

Published: 2017

Journal Articles

m 6 a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia

Ly P Vu, PhD, Brian F Pickering, PhD, Yuanming Cheng, PhD, Zaccara Sara, PhD, Diu Nguyen, PhD, Gerard Minuesa, PhD, Timothy Chou, BS, Arthur Chow, BS, Matthew MacKay, Christopher Famulare, MS, Minal Patel, BA, Francine Garret-Bakelman, MD PhD, Ari Melnick, MD, Martin Carroll, MD, Christopher Mason, PhD, Samie R. Jaffrey, MD PhD, Michael G. Kharas, PhD

Blood (2017) 130 (Supplement 1): 791.

https://doi.org/10.1182/blood.V130.Suppl_1.791.791

Published: 2017

Journal Articles

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Christine M. McMahon, MD, Jonathan Canaani, MD, Bryan Rea, MD, Rachel Lynn Sargent, MD, Jennifer J.D. Morrissette, PhD, David B. Lieberman, MS, CGC, Christopher Watt, MD PhD, Gregory W. Schwartz, PhD, Robert B. Faryabi, PhD, Timothy T. Ferng, MD, Neil P. Shah, MD PhD, Catherine C. Smith, MD, Martin Carroll, MD, Alexander E. Perl, MD

Blood (2017) 130 (Supplement 1): 295.

https://doi.org/10.1182/blood.V130.Suppl_1.295.295

Published: 2017

Journal Articles

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

Miguel Torres Martin, PhD, Grace Jeschke, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Maria E. Figueroa, MD

Blood (2017) 130 (Supplement 1): 3922.

https://doi.org/10.1182/blood.V130.Suppl_1.3922.3922

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

Journal Articles

Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases

Pamela J. Sung, MD PhD, Holly K. Koblish, PhD, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 1250.

https://doi.org/10.1182/blood.V130.Suppl_1.1250.1250

Published: 2017

Journal Articles

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD PhD, Rachel Astles, BA, Alexis Zebrowski, BA, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2016) 128 (22): 755.

https://doi.org/10.1182/blood.V128.22.755.755

Published: 2016

Journal Articles

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Christian Récher, MD PhD, Sarah Bertoli, MD PhD, Muriel Picard, MD, Emilie Bérard, MD PhD, Clément Larrue, PhD, Suzanne Tavitian, MD, Francois Vergez, DVM, PhD, Edwige Yon, Jean Ruiz, MD, Eric Delabesse, PharmD, PhD, Isabelle Luquet, MD, Laetitia Linares, PhD, Martin Carroll, MD, Audrey Sarry, Françoise Huguet, MD, Jean-Emmanuel Sarry, PhD

Blood (2016) 128 (22): 1636.

https://doi.org/10.1182/blood.V128.22.1636.1636

Published: 2016

Journal Articles

Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia

Cihangir Duy, PhD, Matt Teater, M.S., Francine E. Garrett-Bakelman, MD PhD, Tak C Lee, M.S., Cem Meydan, PhD, Jacob Lowell Glass, MD PhD, Meng Li, PhD, Helai Mohammad, PhD, Kimberly Smitheman, Alan H. Shih, MD PhD, Omar Abdel-Wahab, MD, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Monica L. Guzman, PhD, Ryan G. Kruger, PhD, Caretha L. Creasy, PhD, Ross L. Levine, MD, Martin Carroll, MD, Ari Melnick, MD

Blood (2016) 128 (22): 1048.

https://doi.org/10.1182/blood.V128.22.1048.1048

Published: 2016

Journal Articles

Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia

Blood (2016) 128 (22): 599.

https://doi.org/10.1182/blood.V128.22.599.599

Published: 2016

Journal Articles

Acute Myeloid Leukemia Cells Resist Chemotherapy through a Reversible Senescence-like State Maintaining Repopulation Potential

Cihangir Duy, PhD, Matt Teater, M.S., Francine E. Garrett-Bakelman, MD PhD, Martin Carroll, MD, Ari Melnick, MD

Blood (2016) 128 (22): 582.

https://doi.org/10.1182/blood.V128.22.582.582

Published: 2016

Journal Articles

Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2 , and Correlates with More Aggressive AML

Blood (2016) 128 (22): 2877.

https://doi.org/10.1182/blood.V128.22.2877.2877

Published: 2016

Journal Articles

Engraftment of Human MDS Samples in Xenotransplanted Mice Depends on Human Cytokines but Not Mesenchymal Stem Cells (MSC)

Maria Krevvata, MSc, PhD, Cedric Dos Santos, PhD, Xiaochuan Shan, PhD MD, Selene Nunez-Cruz, PhD, Anthony Secreto, Michael Milone, MD PhD, Gwenn Danet-Desnoyers, PhD, Martin Carroll, MD

Blood (2016) 128 (22): 1980.

https://doi.org/10.1182/blood.V128.22.1980.1980

Published: 2016

Journal Articles

In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells

Nesrine Aroua, PhD, Jean-Emmanuel Sarry, PhD, Fabienne De Toni, PhD, Robin Carson, MD BA, Francois Vergez, VD PhD, Estelle Saland, Mayumi Sugita, MD, Martin Carroll, MD, Christian Recher, MDPhD, Gwenn Danet, PhD

Blood (2015) 126 (23): 4269.

https://doi.org/10.1182/blood.V126.23.4269.4269

Published: 2015

NARROW

Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A -Rearranged Acute Lymphoblastic Leukemia

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

m 6 a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Differentiation Response to Quizartinib, a Potent 2 nd Generation FLT3 Inhibitor, in Relapsed FLT3 -Mutant AML Patients Correlates with Specific DNA Methylation Signature Prior to Therapy

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Cytokine Activation of JAK Kinases Rescues FLT3-Mutant AML from FLT3 Inhibition and Requires PIM Kinases

Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL

Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia

Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia

Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Cells Resist Chemotherapy through a Reversible Senescence-like State Maintaining Repopulation Potential

Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2 , and Correlates with More Aggressive AML

Engraftment of Human MDS Samples in Xenotransplanted Mice Depends on Human Cytokines but Not Mesenchymal Stem Cells (MSC)

In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only